Component

HOMA-IR in the histidine metabolic-syndrome trial

Context-specific entity; species, compartment and exposure are stated on each claim.

1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. In a randomized blinded trial of 100 obese women with metabolic syndrome, 4 g/day histidine for 12 weeks reduced HOMA-IR relative to placebo among 92 completers.

    Experimental context and source evidence
    evidence_access
    Primary abstract
    experimental_model
    Women aged 33-51; 50 assigned per arm, 45 histidine and 47 placebo completed.
    limitations
    HOMA-IR is a surrogate; one population and duration. Separate adipocyte experiments do not prove the human mechanism; not a contradiction of isolated microbial-metabolite administration.
    nutrient_topic
    L-Histidine collection; species, compartment, exposure, co-substrates and manipulation remain explicit. · L-Histidine
    plain_language
    A human trial measured improved insulin-resistance-related outcomes in a selected group.
    primary_references
    Histidine supplementation improves insulin resistance through suppressed inflammation in obese women with the metabolic syndrome: a randomised controlled trial. · 2013 · https://pubmed.ncbi.nlm.nih.gov/23361591/ · DOI 10.1007/s00125-013-2839-7

    L-Histidine: supply, catabolism, histamine, receptors and cross-nutrient mechanisms (2026-09-19) · lines 450–456

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Women aged 33-51; 50 assigned per arm, 45 histidine and 47 placebo completed. · source_derived_draft · unverified_draft

    ## histidine-metabolic-human-trial A human trial measured improved insulin-resistance-related outcomes in a selected group. In a randomized blinded trial of 100 obese women with metabolic syndrome, 4 g/day histidine for 12 weeks reduced HOMA-IR relative to placebo among 92 completers. Model: Women aged 33-51; 50 assigned per arm, 45 histidine and 47 placebo completed. Limitations: HOMA-IR is a surrogate; one population and duration. Separate adipocyte experiments do not prove the human mechanism; not a contradiction of isolated microbial-metabolite administration. Evidence access: Primary abstract Histidine supplementation improves insulin resistance through suppressed inflammation in obese women with the metabolic syndrome: a randomised controlled trial. · 2013 · https://pubmed.ncbi.nlm.nih.gov/23361591/ · DOI 10.1007/s00125-013-2839-7
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards